POHMS wants to thank our corporate sponsors. With your support we are able to fulfill the mission of this organization which is to improve the business conditions of the hematology oncology practice.
Please see information below for 2023 Corporate Sponsorship:
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally-discovered product, BRUKINSA® (zanubrutinib) in the United States. To learn more about BeiGene, visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
CHOC was established to function as a group purchasing organization for POHMS members and to share any benefits derived from group purchasing activities.
CHOC selects a preferred vendor, based on a competitive bid process, to provide aggressive drug pricing, payment terms and a variety of related services eligible to CHOC member practices. CHOC's current preferred vendor is McKesson Specialty Health.
CHOC believes every practice has full control over their ability to buy whatever drugs they choose. CHOC’s goal is to assist members with making well-informed decisions at the best available price.
CHOC's vision is to provide an optimal drug-purchasing environment for Hematology Oncology practices.
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.
Founded in 1994, Exelixis is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. Visit our website to learn more: https://www.exelixis.com
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for almost 30 years, using human genetic information to discover, develop, commercialize and manufacture biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions and over 40 projects in the pipeline. The company is the leading provider of anti-tumor therapeutics in theUnited States. With its strength in all areas of the drug development process — from research and development to manufacturing and commercialization — Genentech continues to transform innovative science into breakthrough therapies for patients. For more general information about the company, visit our corporate overview section.
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.
Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across two franchises: Oncology and Inflammation & Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in the U.S., Europe and Japan.
McKesson empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we improve the financial health of our community oncology practice customers and help them provide quality care for patients.
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases.
Lilly is a pioneer in chemotherapy drugs, having introduced vincristine and vinblastine in the 1960s. These anticancer drugs, known as vinca alkaloids, were derived from the rosy periwinkle plant. In 1996, Lilly leveraged this expertise with the introduction of GEMZAR® (gemcitabine HCl for injection) for the treatment of non-small cell lung cancer, pancreatic cancer, and metastatic breast cancer.
For more information about Pharmacyclics LLC, an AbbVie Company, please visit pharmacyclics.com
Taiho Oncology Inc
TAKEDA ONCOLOGY (formerly known as MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY) endeavors to deliver novel medicines to cancer patients worldwide through our science, innovation and passion for improving patients’ lives. We know this mission is not an easy one but we are up to the task: we aspire to cure cancer.
About AbbVie in Oncology
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As the leader in complement biology for over 20 years, Alexion focuses its research efforts on novel molecules and targets in the complement cascade, and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders.
Oncology Supply / ION Solutions
Oncology Supply meticulously distributes chemotherapy, immunotherapy and supportive care products to community oncology practices nationwide from our office and distribution center in Dothan, Alabama. As your trusted supplier and solutions partner, we go beyond the product, delivering the key knowledge that creates opportunities for growth, solutions that optimize critical areas of your practice and insights that lead to more informed decisions. You can count on our vast experience, passion for customer satisfaction, empathetic and responsive service and persistent ingenuity.
Oncology Supply is the exclusive distribution for International Oncology Network (ION).
Astellas Pharma US INC
At EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, our scientific approach in oncology focuses on oncogenic pathways, immuno-oncology, and DNA damage response. To deliver breakthrough cancer therapies, we complement our internal expertise and development programs with scientific collaborations to improve trial designs, accelerate treatment development, and partner on exciting asset programs and integrated innovations. We aim to deliver personalized treatment options that may potentially transform cancer care.
Founded in 1992 in Germany, MorphoSys is dedicated to making innovative biopharmaceuticals to help patients suffering from serious diseases. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys has developed and contributed to the development of more than 100 product candidates, 27 of which are currently in clinical development. MorphoSys is currently headquartered in Planegg, Germany. In 2019, the US head office was established in Boston